-
Zanubrutinib, sold
under the
brand name Brukinsa, is an
anticancer medication used for the
treatment of
mantle cell
lymphoma (MCL), Waldenström's macroglobulinemia...
- pharmaceuticals,
including tislelizumab, a
checkpoint inhibitor, and
zanubrutinib, a Bruton's
tyrosine kinase inhibitor. On 14 November, 2024 the company...
- age at
start of
zanubrutinib was 68
years (IQR 63-75). All
patients received 320mg
zanubrutinib daily.At
initiation of
zanubrutinib, 12
patients (80%)...
- L01EK04
Fruquintinib L01EL01
Ibrutinib L01EL02
Acalabrutinib L01EL03
Zanubrutinib L01EL04
Orelabrutinib L01EL05
Pirtobrutinib L01EM01
Idelalisib L01EM02...
- 5'-Guanidinonaltrindole (5'-GNTI) 6'-Guanidinonaltrindole (6'-GNTI)
Zanubrutinib This set
index page
lists chemical structure articles ****ociated with...
-
Cobimetinib Selumetinib Trametinib EML4-ALK
Crizotinib Entrectinib Lorlatinib Bruton's (BTK)
Acalabrutinib Ibrutinib Orelabrutinib Pirtobrutinib Zanubrutinib...
-
Chronic lymphocytic leukemia (CLL) and
Small lymphocytic lymphoma (SLL)
Zanubrutinib (Brukinsa) for
mantle cell lymphoma,
chronic lymphocytic leukemia (CLL)...
- alone.
Autologous bone
marrow transplantation is a
treatment option.
Zanubrutinib,
another BTK inhibitor, is
indicated for the
treatment of
adults with...
-
duration is
short and
patients typically relapse. In
November 2019,
zanubrutinib (Brukinsa) was
approved in the
United States with an
indication for the...
- anti-cancer
drugs (e.g. venetoclax, atezolizumab, duvelisib, ublituximab,
zanubrutinib, obinutuzumab, olatuzumab, and blinatumomab)
which are used to treat...
